News
Québec City-based biotechnology startup 9Bio is developing a platform for designing drugs that target tumours and spare ...
Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.
Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...
Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...
Merck & Co., Inc.'s 4.09% dividend yield and robust pipeline signal strong growth potential. Click here to read an analysis ...
A novel chimeric antigen receptor T-cell therapy may benefit patients with B-cell lymphomas who previously relapsed following CD19-directed CAR-T, according to results of a phase 1 study.More than 80% ...
A startling new vision of vaccination in America is becoming clearer — one likely to involve fresh scrutiny of established ...
Merck's $11.5 billion deal to acquire Acceleron last year hinged on the promise of pulmonary arterial hypertension (PAH) candidate sotatercept, which has just hit the spot in a much-anticipated ...
Here we use cryogenic electron microscopy to determine the structure of TbAQP2 from Trypanosoma brucei, bound to either the substrate glycerol or to the sleeping sickness drugs, pentamidine or ...
At the start of an unprecedented meeting of vaccine committee of the US Centers for Disease Control and Prevention, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results